共 76 条
[1]
Antzelevitch C., Shimizu W., Cellular mechanisms underlying the long QT syndrome, Curr. Opin. Cardiol., 17, 1, pp. 43-51, (2002)
[2]
Krumpholz L., Wisniowska B., Polak S., Open-access database of literature derived drug-related Torsade de Pointes cases, BMC Pharmacol. Toxicol., 23, (2022)
[3]
Viskin S., Chorin E., Viskin D., Hochstadt A., Schwartz A.L., Rosso R., Polymorphic ventricular tachycardia: terminology, mechanism, diagnosis, and emergency therapy, Circulation, 144, 10, pp. 823-839, (2021)
[4]
Sharifi M., Buzatu D., Harris S., Wilkes J., Development of models for predicting Torsade de Pointes cardiac arrhythmias using perceptron neural networks, BMC Bioinf., 18, (2017)
[5]
Leow J.W.H., Gu Y., Chan E.C.Y., Investigating the relevance of CYP2J2 inhibition for drugs known to cause intermediate to high risk torsades de pointes, Eur. J. Pharmaceut. Sci., 187, (2023)
[6]
Sarganas G., Garbe E., Klimpel A., Hering R.C., Bronder E., Haverkamp W., Epidemiology of symptomatic drug-induced long QT syndrome and torsade de pointes in Germany, Europace, 16, 1, pp. 101-108, (2014)
[7]
Akkaya H., Kisspeptin-10 administration regulates mTOR and AKT activities and oxidative stress in mouse cardiac tissue, J. Evol. Biochem. Physiol., 57, 2, pp. 270-280, (2021)
[8]
Feng P., Yang Y., Liu N., Wang S., Baicalin regulates TLR4/IκBα/NFκB signaling pathway to alleviate inflammation in Doxorubicin related cardiotoxicity, Biochem. Biophys. Res. Commun., 637, pp. 1-8, (2022)
[9]
Karaduman G., Kelleci Celik F., 2D-Quantitative structure-activity relationship modeling for risk assessment of pharmacotherapy applied during pregnancy, J. Appl. Toxicol., 43, 10, pp. 1436-1446, (2023)
[10]
Verderio P., Lecchi M., Ciniselli C.M., Shishmani B., Apolone G., Manenti G., 3Rs principle and legislative decrees to achieve high standard of animal research, Animals, 13, 2, (2023)